{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-26-000074","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2026-07-29T20:08:19+00:00","discovered_at":"2026-07-29T20:09:00.303891+00:00","generated_at":"2026-07-29T20:09:13.531582+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MiMedx Q2 net sales $64M (-35% YoY); to acquire Sanara MedTech for ~$350M","bullets":["Net sales $64M vs $99M YoY; net loss $15M vs net income $10M YoY.","Surgical product sales +15% YoY; Wound sales -61% YoY due to Medicare changes.","Acquiring Sanara MedTech (SMTI) for $35/share ($33 cash + 0.4735 MDXG shares); ~$350M enterprise value.","Consideration represents 46% premium to Sanara's 30-day VWAP; expected close by year-end.","Financing via cash on hand and $300M term loan from Hayfin; FY2026 net sales guidance reiterated at $260-290M."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-26-000074","json":"https://secwatch.observer/filing/0001376339-26-000074.json","markdown":"https://secwatch.observer/filing/0001376339-26-000074.md","text":"https://secwatch.observer/filing/0001376339-26-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000074/0001376339-26-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000074/mdxg-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:09:13.531582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}